Analysis of anti-infection therapeutic schedule analysis for neonatal Streptococcus agalactiae meningitis and discussion on the indications for drug withdrawal

doi:10.5246/jcps.2021.08.056

Journal of Chinese Pharmaceutical Sciences ›› 2021, Vol. 30 ›› Issue (8): 686-691.DOI: 10.5246/jcps.2021.08.056

• Original articles • Previous Articles Next Articles

Analysis of anti-infection therapeutic schedule analysis for neonatal Streptococcus agalactiae meningitis and discussion on the indications for drug withdrawal

Haiyan Wu¹, Tao Wang³, Qian Wang¹, Lin Tang²^,^*()

1 Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, Shandong, China
2 Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China
3 Department of Lean Project Management, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, Shandong, China

Received:2020-12-28 Revised:2021-01-04 Accepted:2021-03-22 Online:2021-08-29 Published:2021-08-29
Contact: Lin Tang

Abstract

Abstract:

The clinical manifestations of neonatal GBS meningitis are as follows: non-specificity, long hospital stay, easy to cause neurological complications, and sequelae. Clinical pharmacist participated in the anti-infective treatment of a neonatal Streptococcus agalactiae meningitis whose cerebrospinal fluid was still abnormal when the drug was stopped. According to the PK/PD characteristics of antibacterial drugs, the permeability of the blood-brain barrier, and the adjustment of the antibiotic dose, the reasons for the decrease in the number of cerebrospinal fluid cells after vancomycin treatment were analyzed. Clinical pharmacists also analyzed the efficacy of linezolid in the treatment of neonatal bacterial meningitis, and discussed the indications for stopping medication when the cerebrospinal fluid is abnormal, so as to improve the safety and effectiveness of antibiotics in the treatment of neonatal bacterial meningitis.

Key words: Streptococcus agalactiae meningitis, Vancomycin, Linezolid, Drug withdrawal indications, Literature analysis

Supporting:

Haiyan Wu, Tao Wang, Qian Wang, Lin Tang. Analysis of anti-infection therapeutic schedule analysis for neonatal Streptococcus agalactiae meningitis and discussion on the indications for drug withdrawal[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(8): 686-691.

Figures/Tables 2

References 15

[1]	Maisey, H.C.; Doran, K.S.; Nizet, V. Recent advances in understanding the molecular basis of group B Streptococcus virulence. Expert. Rev. Mol. Med. 2008, 10, e27.
[2]	Zimmermann, P.; Gwee, A.; Curtis, N. The controversial role of breast milk in GBS late-onset disease. J. Infect. 2017, 74, S34–S40.
[3]	Ju, H.Q.; Bei, F.; Sun, J.H. Clinical analyses of 16 neonatal group B streptococcus meningitis cases. Chin. J. Neonatology. 2016, 3, 178–181.
[4]	Chinese expert consensus on clinical application of vancomycin (2011). Chin. J. New. Drugs Clin. Rem. 2011, 8, 561–573.
[5]	Durham, S.H.; Simmons, M.L.; Mulherin, D.W.; Foland, J.A. An evaluation of vancomycin dosing for complicated infections in pediatric patients. Hosp. Pediatr. 2015, 5, 276–281.
[6]	Nau, R.; Sörgel, F.; Eiffert, H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 2010, 23, 858–883.
[7]	Gilbert, D.N. The Sandford Guide to Antimicrobial Therapy 2018(48th Edition). China Union. Medical. Univ. Press. 2018, 95–96.
[8]	Sullins, A.K.; Abdel-Rahman, S.M. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Pediatr. Drugs. 2013, 15, 93–117.
[9]	Di Paolo, A.; Gori, G.; Tascini, C.; Danesi, R.; Del Tacca, M. Clinical pharmacokinetics of antibacterials in cerebrospinal fluid. Clin. Pharmacokinet. 2013, 52, 511–542.
[10]	Chiappini, E.; Conti, C.; Galli, L.; de Martino, M. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin. Ther. 2010, 32, 66–88.
[11]	Cao, Y.; Cheng, G.Q.; Hou, X.L.; Jiang, L.; Liu, J.; Liu L.; Tang, Y.N.; Tang, Z.Z.; Tong, X.M.; Xiao, J.X.; Yang, H.X.; Yu, J.L.; Zhou, C.L.; Zhou, W.; Zhou, W.H.; Zhou, X.Y.; Zhang, W. Etiology, diagnosis and treatment of bacterial meningitis in newborns. Chin. J. Perinat. Med. 2016, 2, 881–884.
[12]	Yang, H.H.; Li, J. Clinical and prognostic analysis of sepsis caused by Streptococcus agalactiae combined with purulent meningitis in 12 neonates. J. Clin. Pediatr. 2016, 34, 181–184.
[13]	Subspecialty Group of Neurology, the Society of Pediatrics, Chinese Medical Association. Expert consensus on diagnosis and treatment of community acquired bacterial meningitis in children. Chin. J. Pediatr. 2019, 57, 584–591.
[14]	Jiang, Z.F.; Shen, KL.; Shen, Y. Zhu Futang Practice of pediatrics (8th edition). People’s Medical Publishing House. 2015, 987–989
[15]	Wang, D.; Guo, H.; Jin, J.P.; Wu, C.F.; Liang, C.; Huang, Y.J.; Jin, B.; Lu, H.Y.; Lu, X.P.; Zheng, G. Clinical and cerebrospinal fluid follow-up of 25 cases of community-acquired acute bacterial meningitis with abnormal cerebrospinal fluid at the time of drug withdrawal. J. Nanjing Med. Univ. 2017, 37, 880–881.

Analysis of anti-infection therapeutic schedule analysis for neonatal Streptococcus agalactiae meningitis and discussion on the indications for drug withdrawal

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 15

Related Articles 7

Recommended Articles

Metrics

Comments

[1]	Xinyu Chang, Lijuan Han, Yang Liu, Zheng Fan, Jiankun Wu. Analysis of adverse drug reactions caused by carbapenems and review of related literature [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 835-841.
[2]	Ye Yuan, Bo Yu, Zhenzhen Yang, Weichong Dong, Xiuling Yang. Pharmacological monitoring and literature analysis of dagliflozin in patients with hypovolemia [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(9): 718-722.
[3]	Yanyu Pei, Jihui Hao, Wenqi Duan, Yujing Zheng, Ming Zhao, Liping Yang. Severe and lethal adverse reactions of linezolid—a summary analysis of case reports [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(2): 153-161.
[4]	Chaohui Wu, Huifen Lin, Weiwei Lin, Yiwei Liu, Xiang You, Cuihong Lin, Rongfang Lin, Dayong Zeng, Pinfang Huang. A prospective cohort study on the relationship between vancomycin steady-state trough concentration and efficacy and safety in Chinese adults [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(5): 341-354.
[5]	Jin Zhang, Weiwei Lin, Wei Wu, Xianzhong Guo, Pinfang Huang, Xinhua Lin, Zheng Jiao, Changlian Wang. Population pharmacokinetics of vancomycin in Chinese elderly patients and its application for dose individualisation [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(4): 260-271.
[6]	Jinlian Zhang, Jia Zhou, Jihui Chen, Ting Chen, Yan Liu, Huaiping Tian, Jian Zhang. Analysis for the vancomycin plasma concentration data in infants by clinical pharmacists [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(4): 263-266.
[7]	Zhikang Ye, Huilin Tang, Jingli Duan, Suodi Zhai^*. Efficacy and safety of fidaxomicin versus vancomycin for Clostridium difficile infection: systematic review and meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2013, 22(6): 508-515.